Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Prospective Remapping With Concomitant Left Atrial Appendage Occlusion to Ensure Durable Electroporation Study

NCT: NCT07620262 · RECRUITING

NCT IDNCT07620262
StatusRECRUITING
Start Date2026-05-01
Completion2028-07
SponsorNorthwell Health (OTHER)
First posted
Last updated

Brief Summary

This is a single-arm, open label, clinical outcome study to research the durability (success) of receiving a pulsed field ablation (PFA) per standard of care for treatment of atrial fibrillation during a subsequent procedure for the insertion of a left atrial appendage occlusion (LAAO) device. The reassessment of the initial ablation will be performed with or without additional ablation if needed.

Frequently Asked Questions

What is Prospective Remapping With Concomitant Left Atrial Appendage Occlusion to Ensure Durable Electroporation Study?

Prospective Remapping With Concomitant Left Atrial Appendage Occlusion to Ensure Durable Electroporation Study is a clinical trial registered under NCT07620262. Current status: RECRUITING.

What is the status of NCT07620262?

The current status of NCT07620262 (Prospective Remapping With Concomitant Left Atrial Appendage Occlusion to Ensure Durable Electroporation Study) is: RECRUITING.

When did Prospective Remapping With Concomitant Left Atrial Appendage Occlusion to Ensure Durable Electroporation Study start?

Prospective Remapping With Concomitant Left Atrial Appendage Occlusion to Ensure Durable Electroporation Study started on 2026-05-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑